Pfizer says it will seek FDA approval for a COVID-19 vaccine booster dose

Pfizer and BioNTech say that a third COVID-19 booster dose given about six months after the second shot improves vaccine efficacy against new coronavirus variants and that this is backed by initial data from their study on booster shots. While the COVID-19 vaccine remains 95% effective in preventing serious cases, efficacy against catching the disease has started to decrease in populations in the UK and Israel about six months after getting the second vaccine shot, according to Pfizer Chief Scientific Officer Mikael Dolsten. The company said it plans to seek emergency authorization approval from the US Food and Drug Administration in August, according to The Associated Press.